Eli Lilly (NYSE: LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth ...

But shares of Eli Lilly have gained about 800% since that same month, when CEO Dave Ricks took over the company. Mounting pressure also came from the powerful Novo Nordisk Foundation ...

But shares of Eli Lilly have gained about 800% since that same month, when CEO Dave Ricks took over the company. Feeling out of the loop? We'll catch you up on the news you need to know with the ...

WestEnd Advisors LLC grew its position in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down as competition in the weight-loss drug space pressured the company's stock ... rivals such as Eli Lilly to dominate the highly ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Eli Lilly is further expanding its RNA medicine ... which the Seongham, South Korea-based company has touted as enabling “precise RNA editing and has broad applicability across multiple ...